EXEL vs ISRG
Exelixis vs Intuitive Surgical — AI-powered side-by-side comparison
VS
ISRG
Intuitive Surgical
60
Buy
| Metric | EXEL | ISRG |
|---|
| AI Score |
67
|
60
|
| Price |
$56.73
|
$371.73
|
| P/E Ratio |
16.58×
|
42.21×
|
| ROE |
36.2%
|
16.0%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
96.5%
|
66.7%
|
| Debt / Equity |
0.09×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
58.6
|
40.0
|
| Beta |
0.422
|
1.46
|
| Expected Upside |
+5.5%
|
+18.5%
|
AI Committee View
Current Innellis committee reasoning for EXEL versus ISRG.
EXEL leads by 7 points.
EXEL scores 67/100 (Buy) versus ISRG at 60/100 (Buy).
EXEL Committee View
83% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- P/E of 14.5 is inexpensive for the broad market — Value
- ROE of 42.5% shows genuine earnings power backing the valuation — Value
- EPS growing 52.7% YoY — Growth
Bear Case
- Price-to-book of 5.4x prices in significant intangible value — Value
ISRG Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 17.8% shows genuine earnings power backing the valuation — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- P/E of 45.2 is expensive by classic value standards — Value
- Price-to-book of 11.3x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical